test
test
test
test
test
test
test
test
test
test
Role of DPO (Darbepoetin Alfa) - Anemia in CKD
Role of DPO (Darbepoetin Alfa) - Anemia in CKD
Role of DPO (Darbepoetin Alfa) - Anemia in CKD
Role of DPO (Darbepoetin Alfa) - Anemia in CKD
Role of DPO (Darbepoetin Alfa) - Anemia in CKD
Role of DPO (Darbepoetin Alfa) - Anemia in CKD
Role of DPO (Darbepoetin Alfa) - Anemia in CKD
Role of DPO (Darbepoetin Alfa) - Anemia in CKD
Role of DPO (Darbepoetin Alfa) - Anemia in CKD
Role of DPO (Darbepoetin Alfa) in Anemia
Role of DPO (Darbepoetin Alfa) in Anemia
Role of DPO (Darbepoetin Alfa) in Anemia
Finerenone reduces 24-h, daytime, and night-time systolic blood pressure in patients with chronic kidney disease and type 2 diabetes, says a latest study published in the Journal of Hypertension.
This phase 2b trial assessed the effects of finerenone on 24-h ambulatory BP in 823 patients with type 2 diabetes and chronic kidney disease. The study included patients with albumin-to-creatinine ratio ≥30 mg/g and estimated glomerular filtration rate of 30-90 ml/min per 1.73 m2. The participants were randomized to receive wither finerenone (1.25-20 mg once daily in the morning) administered over 90 days or placebo. Ambulatory BP monitoring (ABPM) over 24 h was performed in a subset of 240 patients at screening, Day 60, and Day 90.
At Day 90, the 24-h ABPM systolic BP (SBP) was -8.3 mmHg for finerenone 10 mg (n = 27), -11.2 mmHg for finerenone 15 mg (n = 34), and -9.9 mmHg for finerenone 20 mg (n = 31). Mean daytime and night-time SBP recordings were similarly reduced and finerenone did not increase the incidence of SBP dipping.
According to the results, finerenone can reduce 24-h, daytime, and night-time SBP and these changes in the BP can be persistent over 24 h with once-daily dosing in the morning.
Finerenone reduces 24-h, daytime, and night-time systolic blood pressure in patients with chronic kidney disease and type 2 diabetes, says a latest study published in the Journal of Hypertension.
This phase 2b trial assessed the effects of finerenone on 24-h ambulatory BP in 823 patients with type 2 diabetes and chronic kidney disease. The study included patients with albumin-to-creatinine ratio ≥30 mg/g and estimated glomerular filtration rate of 30-90 ml/min per 1.73 m2. The participants were randomized to receive wither finerenone (1.25-20 mg once daily in the morning) administered over 90 days or placebo. Ambulatory BP monitoring (ABPM) over 24 h was performed in a subset of 240 patients at screening, Day 60, and Day 90.
At Day 90, the 24-h ABPM systolic BP (SBP) was -8.3 mmHg for finerenone 10 mg (n = 27), -11.2 mmHg for finerenone 15 mg (n = 34), and -9.9 mmHg for finerenone 20 mg (n = 31). Mean daytime and night-time SBP recordings were similarly reduced and finerenone did not increase the incidence of SBP dipping.
According to the results, finerenone can reduce 24-h, daytime, and night-time SBP and these changes in the BP can be persistent over 24 h with once-daily dosing in the morning.
Finerenone reduces 24-h, daytime, and night-time systolic blood pressure in patients with chronic kidney disease and type 2 diabetes, says a latest study published in the Journal of Hypertension.
This phase 2b trial assessed the effects of finerenone on 24-h ambulatory BP in 823 patients with type 2 diabetes and chronic kidney disease. The study included patients with albumin-to-creatinine ratio ≥30 mg/g and estimated glomerular filtration rate of 30-90 ml/min per 1.73 m2. The participants were randomized to receive wither finerenone (1.25-20 mg once daily in the morning) administered over 90 days or placebo. Ambulatory BP monitoring (ABPM) over 24 h was performed in a subset of 240 patients at screening, Day 60, and Day 90.
At Day 90, the 24-h ABPM systolic BP (SBP) was -8.3 mmHg for finerenone 10 mg (n = 27), -11.2 mmHg for finerenone 15 mg (n = 34), and -9.9 mmHg for finerenone 20 mg (n = 31). Mean daytime and night-time SBP recordings were similarly reduced and finerenone did not increase the incidence of SBP dipping.
According to the results, finerenone can reduce 24-h, daytime, and night-time SBP and these changes in the BP can be persistent over 24 h with once-daily dosing in the morning.
The findings of a recent study on type 2 diabetes (T2D) show that people who develop diabetes at an early age had greater chances of developing diabetic complications such as neuropathy, retinopathy, carotid artery plaque, and chronic kidney disease (CKD).
The results of the study were published in the journal, Diabetes & Metabolism. The observational study comprised of 10,447 individuals who suffered from at least one form of diabetic complications- 1,791 people were young-onset T2D (less than 40 years) while 8,656 were late-onset T2D (greater than or equal to 40 years) individuals.
Based on the results obtained from cluster analysis, it was found that people with young-onset diabetes had a higher chance of developing diabetic complications as compared to late-onset T2D cases. However, the prevalence of having diabetic neuropathy remained at a higher level irrespective of the age of diabetes onset.
The findings of a recent study on type 2 diabetes (T2D) show that people who develop diabetes at an early age had greater chances of developing diabetic complications such as neuropathy, retinopathy, carotid artery plaque, and chronic kidney disease (CKD).
The results of the study were published in the journal, Diabetes & Metabolism. The observational study comprised of 10,447 individuals who suffered from at least one form of diabetic complications- 1,791 people were young-onset T2D (less than 40 years) while 8,656 were late-onset T2D (greater than or equal to 40 years) individuals.
Based on the results obtained from cluster analysis, it was found that people with young-onset diabetes had a higher chance of developing diabetic complications as compared to late-onset T2D cases. However, the prevalence of having diabetic neuropathy remained at a higher level irrespective of the age of diabetes onset.
The findings of a recent study on type 2 diabetes (T2D) show that people who develop diabetes at an early age had greater chances of developing diabetic complications such as neuropathy, retinopathy, carotid artery plaque, and chronic kidney disease (CKD).
The results of the study were published in the journal, Diabetes & Metabolism. The observational study comprised of 10,447 individuals who suffered from at least one form of diabetic complications- 1,791 people were young-onset T2D (less than 40 years) while 8,656 were late-onset T2D (greater than or equal to 40 years) individuals.
Based on the results obtained from cluster analysis, it was found that people with young-onset diabetes had a higher chance of developing diabetic complications as compared to late-onset T2D cases. However, the prevalence of having diabetic neuropathy remained at a higher level irrespective of the age of diabetes onset.
